This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Apollo Endosurgery Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Chas McKhann

Algemeen directeur

US$2.8m

Totale compensatie

Percentage CEO-salaris	19.8%
Dienstverband CEO	2.1yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	5.2yrs

Recente managementupdates

Recent updates

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

Mar 03

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

Feb 10

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

Jan 31

Assessing Apollo Endosurgery

Dec 27

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

Dec 27

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

Dec 01

Apollo Endosurgery EPS beats by $0.10, beats on revenue

Nov 05

Analyse CEO-vergoeding

Hoe is Chas McKhann's beloning veranderd ten opzichte van Apollo Endosurgery's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2022	US$3m	US$550k	-US$40m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$9m	US$375k	-US$25m

Compensatie versus markt: Chas's total compensation ($USD2.78M) is about average for companies of similar size in the US market ($USD2.67M).

Compensatie versus inkomsten: Chas's compensation has been consistent with company performance over the past year.

CEO

Chas McKhann (53 yo)

2.1yrs

Tenure

US$2,780,544

Compensatie

Mr. Charles S. McKhann, also known as Chas, serves as President, Chief Executive Officer and Director at Apollo Endosurgery, Inc since March 01, 2021. He served as Chief Commercial Officer at Torax Medical...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Charles McKhann	CEO, President & Director	2.1yrs	US$2.78m	0.39% $ 2.2m
Jeffrey Black	CFO, Secretary & Treasurer	1.7yrs	US$1.34m	0.18% $ 1.0m
John Molesphini	Executive Vice President of Operations	5yrs	US$662.23k	0.079% $ 460.8k
Sergey Kantsevoy	Co-Founder and Innovation Partner	no data	geen gegevens	geen gegevens
Anthony Kalloo	Co-Founder and Innovation Partner	no data	geen gegevens	geen gegevens
Robert Hawes	Co-Founder and Innovation Partner	no data	geen gegevens	geen gegevens
Peter Cotton	Co-Founder and Innovation Partner	18.3yrs	geen gegevens	geen gegevens
Christopher Gostout	Co-Founder & Chief Medical Officer	no data	US$1.16m	0.062% $ 361.2k
Sydney Chung	Co-Founder and Innovation Partner	no data	geen gegevens	geen gegevens
Pankaj Pasricha	Co-Founder	18.3yrs	geen gegevens	geen gegevens
John Gillings	Investor Relations Manager	no data	geen gegevens	geen gegevens
Brian Szymczak	Vice President of Legal & Compliance	3.6yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: APEN's management team is considered experienced (4.3 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Charles McKhann	CEO, President & Director	2.1yrs	US$2.78m	0.39% $ 2.2m
John Barr	Independent Chairman of the Board	4.1yrs	US$193.24k	0.051% $ 298.6k
Julie Shimer	Independent Director	4.9yrs	US$164.49k	0.038% $ 218.0k
Richard McGaughy	Independent Director	11.3yrs	US$165.15k	geen gegevens
William McClellan	Independent Director	8.9yrs	US$169.49k	0.047% $ 270.3k
Adrian Park	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Mark Talamini	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Santiago Horgan	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jay Redan	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Steve McCarus	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jeffrey Marks	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
David Pacitti	Independent Director	5.4yrs	US$159.70k	0.0067% $ 38.9k

5.2yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: APEN's board of directors are considered experienced (5.2 years average tenure).

This company has been acquired

Apollo Endosurgery Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought US$229k worth of stock

Apollo Endosurgery, Inc. Announces Board Changes

CEO, President & Director recently sold US$504k worth of stock

Recent updates

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Price target decreased to US$11.75

Boston Scientific Corporation (NYSE:BSX) entered into a definitive merger agreement to acquire Apollo Endosurgery, Inc. (NasdaqGM:APEN) for approximately $440 million.

Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Endosurgery, Inc. Raises Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Consensus forecasts updated

Is Apollo Endosurgery (NASDAQ:APEN) Using Too Much Debt?

Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Endosurgery, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022

Apollo Endosurgery, Inc. to Report Q2, 2022 Results on Aug 02, 2022

FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG(TM) and Apollo REVISE(TM), New Endoscopic Systems for Patients with Obesity

Apollo Endosurgery, Inc. Announces Executive Changes

Apollo Endosurgery, Inc.(NasdaqGM:APEN) dropped from Russell Microcap Value Index

Apollo Endosurgery, Inc., Annual General Meeting, Jun 14, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Apollo Endosurgery, Inc. to Report Q1, 2022 Results on May 03, 2022

Apollo Endosurgery, Inc. Appoints Jeannette Bankes to Board of Directors

CFO, Secretary & Treasurer recently bought US$229k worth of stock

Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?

Full year 2021 earnings: EPS exceeds analyst expectations

Consensus forecasts updated

Apollo Endosurgery, Inc. Announces Board Changes

Price target decreased to US$12.67

Apollo Endosurgery, Inc. Provides Preliminary, Un-Audited Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.11 loss in 3Q 2020)

CEO, President & Director recently sold US$504k worth of stock

CEO, President & Director recently sold US$504k worth of stock

Chief Financial Officer recently bought US$219k worth of stock

Consensus forecasts updated

Price target increased to US$14.00

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.30 loss in 2Q 2020)

Is Apollo Endosurgery, Inc. (NASDAQ:APEN) Trading At A 20% Discount?

Apollo Endosurgery: New Management Bounce Makes Weight Loss Specialist A Buy

Insider recently sold US$129k worth of stock

Price target increased to US$11.25

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.49 loss in 1Q 2020)

Is Apollo Endosurgery (NASDAQ:APEN) A Risky Investment?

Apollo Endosurgery EPS beats by $0.05, beats on revenue

A Look At The Intrinsic Value Of Apollo Endosurgery, Inc. (NASDAQ:APEN)

Independent Chairman of the Board recently bought US$59k worth of stock

Apollo Endosurgery, Inc. Announces Departure of Todd Newton as Chief Executive Officer

What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?

New 90-day high: US$6.10

Full year 2020 earnings released: US$0.99 loss per share (vs US$1.27 loss in FY 2019)

Insider recently bought US$86k worth of stock

Revenue beats expectations, earnings disappoint

Apollo Endosurgery, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Insider recently bought US$146k worth of stock

Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares

Apollo Endosurgery, Inc. Announces Management Changes, Effective as of March 1, 2021

New 90-day high: US$4.86

We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt

Assessing Apollo Endosurgery

If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%

Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?

New 90-day high: US$2.30

Analysts increase revenue estimates to US$40.2m

Third quarter 2020 earnings released: US$0.11 loss per share

Revenue beats expectations, earnings disappoint

Apollo Endosurgery EPS beats by $0.10, beats on revenue

New 90-day high: US$1.79

New 90-day low - US$1.31

First half earnings released